Close Menu

NEW YORK – Basel, Switzerland-based Basilea Pharmaceutica on Monday announced that it has begun a Phase I/II trial evaluating its investigational agent derazantinib as a treatment for patients with advanced gastric cancer whose tumors have FGFR alterations.

The study, dubbed FIDES-03, will assess derazantinib, an inhibitor of FGFR1, FGFR2, and FGFR3, both as a monotherapy and in combination with the PD-L1 inhibitor atezolizumab (Roche's Tecentriq). Basilea will sponsor the study, while Roche will supply atezolizumab.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.